(1S,2S)-Bortezomib

TargetMol
Product Code: TAR-T10061
Supplier: TargetMol
CodeSizePrice
TAR-T10061-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-2mg2mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-5mg5mg£301.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-1mL1 mL * 10 mM (in DMSO)£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-25mg25mg£710.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-50mg50mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10061-100mg100mg£1,235.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a reversible and selective inhibitor of the proteasome with a Ki of 0.6 nM for 20S proteasome.
CAS:
1132709-14-8
Formula:
C19H25BN4O4
Molecular Weight:
384.24
Pathway:
Proteases/Proteasome; Ubiquitination
Purity:
0.9833
SMILES:
[C@H](CC1=CC=CC=C1)(C(N[C@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2
Target:
Proteasome

References

1. Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55(7):697-705. 2. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. 3. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.